EGFRs (epidermal growth factor receptors), VEGFRs (vascular endothelial growth factor receptors), PDGFRs (platelet-derived growth factor receptors), FGFRs (fibroblast growth factor receptors), ROR1 and ROR2 (receptor tyrosine kinase-like orphan receptors 1 and 2), and other RTKs are overexpressed or mutated in solid or hematologic malignancies, activating Ras/MAPK, PI3K/Akt, JAK/STAT, or PLCγ metabolic pathways, thus contributing to enhanced cell proliferation, differentiation, migration, and cell death regulation [14]. Here, ROR1 is linked to hematologic disorder.